FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation

Jan.07
FDA Guidelines on Tobacco Product Analysis and Testing Methods Validation
FDA releases finalized guidelines on tobacco product analysis testing methods, providing manufacturers with support for regulatory submissions.

On January 6, the U.S. Food and Drug Administration (FDA) released the final version of the "Validation and Confirmation of Tobacco Product Analysis Methods" guidance, providing information and recommendations for tobacco manufacturers to support their submissions.


This guide provides detailed instructions for manufacturers on how to submit verified and validated data on analysis procedures and testing methods to the FDA for use in submissions including premarket tobacco product applications, substantial equivalence reports, and modified risk tobacco product applications.


Before being able to legally sell new tobacco products or modified risk tobacco products in the United States, companies must first submit an application to the FDA and receive approval. These applications typically require data and information to support the analytical methods used for testing tobacco products, and this guideline provides manufacturers and laboratories with scientifically sound information organization and presentation methods.


The principles described in this guide can also be applied to the writing of reports on harmful and potentially harmful constituents data required by tobacco product manufacturers and importers.


The draft version of this guide was released in 2021, allowing the public to provide feedback on the content. After considering this feedback, the FDA made adjustments to the final version of the guide, including updating the definition of "tobacco products" to include non-tobacco nicotine, adjusting the content to reflect the final PMTA and SE regulations, and updating and adding definitions for multiple terms. The final version of the guide also includes updated examples of alternative validation methods.


These suggestions are not legally binding and do not create legal obligations. In addition, the FDA acknowledges that there may be alternative validation procedures, such as statistical testing, that differ from the recommendations in this guide.


For applicants looking to introduce new tobacco products into the market, the FDA promises to continue providing information and resource support, including this recently released guide. The FDA has already issued regulations such as the PMTA final rule and regularly posts additional resources on its website and social media, such as application tips and webinars.


Compliance experts and consultants have provided the following analysis of the guidelines.


The U.S. FDA has issued this guide to provide tobacco manufacturers with guidance on conducting scientific validation and confirmation of analytical testing methods when submitting PMTA (premarket tobacco product application), SE (substantial equivalence application), and MRTPA (modified risk tobacco product application). This guide focuses on analytical testing of tobacco product ingredients, components, and additives, as well as issues related to chemical stability testing of finished tobacco products. It can also be used to guide testing and analysis of harmful and potentially harmful constituents (HPHC) in finished tobacco products, as well as other smoke or aerosol emissions. The guide aims to assist tobacco product manufacturers and analytical laboratories in collecting and presenting scientifically valid data and information to support analytical methods for submission to regulatory authorities for finished tobacco products. The recommendations in this guide will help the FDA better understand and evaluate the reliability of the data provided in regulatory submissions.


Click to read the final version of the guidelines for the validation and confirmation of analytical methods for tobacco products.


Readers are welcome to leave comments and get in touch with 2Firsts. Please contact: info@2firsts.com, or connect with 2Firsts CEO Alan Zhao on LinkedIn.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress Calls on FDA to Allocate at Least $200 Million for ENDS Enforcement, Multi-Agency Task Force to Target Illegal e-Cigarette Imports. IKE Tech and Ispire Utilize Blockchain and Age Verification Technology to Support Regulation, Submit Chips as Part
Congress demands FDA allocate at least $200 million for ENDS enforcement; multi-agency task force to combat illegal e-cigarette imports.
Nov.18 by 2FIRSTS.ai
Hungary’s Continental Tobacco Launches New Slay Nicotine Pouch Brand in UK Targeting Female Consumers
Hungary’s Continental Tobacco Launches New Slay Nicotine Pouch Brand in UK Targeting Female Consumers
Hungary’s Continental Tobacco Group has launched its Slay nicotine pouch brand in the UK, featuring compact, pastel-toned packaging and backed by a multi-million-pound investment and retail pilot programme to build its presence in the local market.
Dec.03 by 2FIRSTS.ai
Product | FASTA Unveils New U.S. Offering, Citing “Made in USA” Status and Texas Compliance
Product | FASTA Unveils New U.S. Offering, Citing “Made in USA” Status and Texas Compliance
FASTA has launched a new disposable, the FASTA ALIEN 51K, on U.S. online channels. Retailer Mi-Pod describes the product as “assembled and filled in the U.S.” and labels it as compliant with Texas e-cigarette registration requirements. The ALIEN 51K is now available via Mi-Pod and Vaping, with a suggested retail price of about $19.99.
Nov.12 by 2FIRSTS.ai
Illegal tobacco syndicate dominates Australia’s vape market through threats and extortion
Illegal tobacco syndicate dominates Australia’s vape market through threats and extortion
Australia’s The Age has revealed that a local tobacco cartel is working with a crime syndicate to dominate the illicit vape trade. The Australian Border Force (ABF) intercepted 115,200 vapes worth A$4.5 million disguised as “furniture” at Sydney port. Authorities say over 12 million illegal vapes have been seized since 2024.
Nov.03
Kazakhstan Denies Rumors of Easing Hookah and Vape Restrictions: Deputy Interior Minister Reaffirms “Zero Tolerance” for Vapes
Kazakhstan Denies Rumors of Easing Hookah and Vape Restrictions: Deputy Interior Minister Reaffirms “Zero Tolerance” for Vapes
Kazakhstan’s Deputy Interior Minister Sanzhar Adilov (Санжар Адилов) addressed social media rumors that the government may ease restrictions on hookahs and vapes. He confirmed that hookah regulations are under interagency review, but the strict ban on vapes remains unchanged and has recently been reinforced with criminal liability.
Nov.13 by 2FIRSTS.ai
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
PMI’s Smoke-Free Playbook: What Jacek Olczak Really Told Wall Street
At the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, PMI CEO Jacek Olczak delivered a clear message: the company’s smoke-free shift is now its central strategy. From ZYN’s surge in the U.S. to IQOS’s global momentum and a changing regulatory tone, his remarks sounded less like an earnings update and more like a declaration of PMI’s smoke-free future.
PMI
Dec.03